US FDA's PADA committee recommends approval of PT027 to treat asthma in people aged 18 years and older

The US Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of [...]